Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
| Descriptor ID |
D006495
|
| MeSH Number(s) |
D09.698.373.400.300
|
| Concept/Terms |
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
|
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Apixaban for Prevention of Thromboembolism in Pediatric Heart?Disease. J Am Coll Cardiol. 2023 12 12; 82(24):2296-2309.
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):790-802.
-
Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol. 2020 Apr; 31(4):537-543.
-
Review: The quality of evidence is very low for periprocedural bridging in patients receiving VKA for VTE. Ann Intern Med. 2019 06 18; 170(12):JC64.
-
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 01; 173:158-163.
-
Pharmacologic Thromboprophylaxis in Obstetrics: Broader Use Demands Better Data. Obstet Gynecol. 2017 02; 129(2):382.
-
National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstet Gynecol. 2016 10; 128(4):688-98.
-
Resolution of Hepatic Artery Thrombosis in 2 Pediatric Liver Transplant Patients. J Pediatr Gastroenterol Nutr. 2016 Apr; 62(4):546-9.
-
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood. 2015 Dec 10; 126(24):2541-7.
-
Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Ann Surg. 2014 Jun; 259(6):1073-9.